SPDR S&P Biotech ETF (XBI) sees strength amid more deal headlines

August 5, 2022 11:48 AM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

SPDR S&P Biotech ETF (NYSE: XBI) sees strength amid more deal headlines. Today it's PFE/GBT. The sector ETF is up 1.7%

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

ETFs, Trader Talk

Related Entities

Standard & Poor's